C-Reactive Protein for Pulmonary Tuberculosis Screening and Treatment Response Monitoring in Children

Area of Science:

• Pediatrics
• Infectious Diseases
• Biomarker Research

Background:

• Pulmonary tuberculosis (TB) remains a significant health challenge in children, particularly in resource-limited settings.
• Accurate diagnostic tools and effective treatment monitoring are crucial for pediatric TB management.
• C-reactive protein (CRP) is an inflammatory marker with potential utility in infectious disease contexts.

Purpose of the Study:

• To assess the role of C-reactive protein (CRP) as a biomarker for diagnosing pulmonary tuberculosis (TB) in Kenyan children.
• To evaluate CRP's effectiveness in monitoring treatment response among pediatric TB patients.
• To determine if baseline CRP levels influence its utility in TB management.

Main Methods:

• A study involving 292 Kenyan children was conducted to evaluate CRP levels.
• CRP levels were measured for diagnostic assessment and during TB treatment.
• Statistical analyses were performed to correlate CRP levels with TB diagnosis and treatment outcomes.

Main Results:

• The diagnostic sensitivity of CRP for pulmonary TB in children was suboptimal, ranging from 35.5% to 50.0%.
• A significant decrease in median CRP levels was observed during TB treatment in children with both confirmed (P = .02) and unconfirmed (P < .001) TB.
• This decrease was most pronounced in children with elevated baseline CRP (≥5 mg/L), observed in 40% of cases.

Conclusions:

• C-reactive protein (CRP) is not a sensitive standalone biomarker for diagnosing pulmonary TB in children.
• CRP levels demonstrate utility in monitoring the response to TB treatment in pediatric populations.
• Monitoring CRP reduction, particularly in children with initially high levels, can provide valuable insights into treatment efficacy.